Stories about Gesundheit

17.07.2014 – 11:27
Deutsche Gesetzliche Unfallversicherung (DGUV)
Publication of the programme for the World Congress on Safety and Health at Work 2014
Berlin (ots) - Top-level guests at the world's biggest safety & health convention - Day passes now bookable - Information for journalists A world without serious accidents at work - this is the vision that will be discussed by politicians, scientists and experts from all over the world at the XX World Congress on Safety and Health at Work, which is taking place in ...
more
05.05.2014 – 07:00
DocCheck Research
One Million DocCheckers / Europe's largest healthcare community reaches seven figures
Cologne (ots) - The DocCheck Community reached the magic number of one million users in April, putting it in a clear pole position among European healthcare communities. DocCheck has been providing GPs, consultants, students, pharmacists, nurses, pharmacy technicians and paramedics with healthcare-related news and services for more than 15 years. Launched in 1996 with ...
more
14.11.2013 – 10:00
Deutsche Gesetzliche Unfallversicherung (DGUV)
Last chance to submit contributions to the XX World Congress on Safety and Health at Work 2014
Berlin (ots) - The registration period for contributions to the XX World Congress on Safety and Health at Work 2014 ends on the 30th of November 2013. Participants who wish to make a contribution to a symposium are invited to submit an English-language summary thereof online at www.safety2014germany.com/papers. ...
more
16.10.2013 – 08:00
BG ETEM - Berufsgenossenschaft Energie Textil Elektro Medienerzeugnisse
International Media Festival for Prevention: The best films for occupational safety and health will be awarded
Frankfurt (ots) - Films and multimedia applications are vital instruments of safety and health at work. Whether for the purpose of increasing risk awareness on the part of employees or providing information on comprehensive safety topics: moving images support the transfer of knowledge. Media makers have to keep ...
more
19.04.2012 – 13:51
DocCheck Research
DocCheck goes India / DocCheck announces cooperation with India-based healthcare service
Cologne (ots) - Well-spread throughout Europe, DocCheck continues to expand into new markets. In order to provide healthcare professionals around the globe with its unique services, DocCheck has now settled an exclusive cooperation with Indian experts D2L Pharma Research Solutions. The cooperation encompasses the fast-growing healthcare market of India, thus granting ...
more
19.04.2011 – 09:15
BASF SE
World Malaria Day: when a simple initiative conveys great results
Limburgerhof, Germany (ots) - - Interceptor® bed nets key factor for decrease in malaria infection in Jabote community (Brazil) - Positive spiral effect: less malaria, more kids in school - Cross reference: Pictures are available via epa european pressphoto agency and can be downloaded free of charge at: http://www.presseportal.de/pm/16344/basf_se/?keygroup=bild - April 25th marks the fourth annual celebration of World ...
more
22.12.2010 – 10:16
KfW IPEX-Bank
German Ambulance Vehicles for Ghana
Frankfurt am Main (ots) - - KfW IPEX-Bank arranges export financing of Volkswagen vehicles converted into ambulances by WAS - Contribution to a change for the better in ambulatory care for the rural population in Ghana KfW IPEX-Bank finances the conversion of more than 150 Volkswagen vans into ambulance vehicles and mobile clinics and their delivery to the Republic of Ghana. The loan agreement was signed in December and ...
more
17.12.2009 – 13:34
Boehringer Ingelheim
Boehringer Ingelheim Initiates First Phase III Clinical Trial in Ovarian Cancer
Ingelheim, Germany (ots/PRNewswire) - Boehringer Ingelheim announced today the initiation of a new phase III clinical trial to evaluate one of its two late-stage oncology pipeline compounds for the treatment of patients with advanced ovarian cancer. The clinical study, called LUME-Ovar-1 trial, investigates the compound BIBF 1120, a novel oral anti-angiogenic agent[1], ...
more
16.11.2009 – 14:18
Boehringer Ingelheim
Flibanserin Demonstrates Efficacy and Tolerability in Pivotal Phase III Trials in Pre-Menopausal Women With Hypoactive Sexual Desire Disorder (HSDD)
Ingelheim, Germany, November 16 (ots/PRNewswire) - - Results Support Flibanserin as a Potential Treatment for HSDD, an Under-Recognised Women's Sexual Health Condition - For Medical Media, Outside the US Only Data from pooled, pivotal Phase III clinical trials demonstrate that flibanserin 100mg taken once daily at ...
more
14.10.2009 – 09:08
Boehringer Ingelheim
Boehringer Ingelheim Receives Approval From the European Commission for Mirapexin(R)/Sifrol(R) Prolonged-Release, Once Daily Tablet for the Treatment of Parkinson's Disease
Ingelheim, Germany (ots/PRNewswire) - - New Formulation Brings the Established Efficacy of Mirapexin(R)/Sifrol(R) to Patients With Parkinson's Disease in the Convenience of a Once Daily Dose Boehringer Ingelheim today announced that the Mirapexin(R)/Sifrol(R) (pramipexole) new prolonged-release , once daily tablet ...
more
28.09.2009 – 08:08
Boehringer Ingelheim
Boehringer Ingelheim's Diabetes Pipeline Continues to Advance as the Company Announces Conclusion of Robust Phase III Pivotal Trials Programme for linagliptin
Ingelheim, Germany (ots/PRNewswire) - - For Non-US Healthcare Media Following the release of linagliptin Phase II data earlier this year, Boehringer Ingelheim has now announced the conclusion of the linagliptin pivotal Phase III clinical trials. The company confirmed that first results from the Phase III clinical ...
more
03.08.2009 – 07:04
Boehringer Ingelheim
Boehringer Ingelheim to Commence Phase III Study Investigating the Role of BIBW 2992 (Tovok(TM)) as First-Line Treatment for Non-Small Cell Lung Cancer (NSCLC) Patients With EGFR Mutations
Ingelheim, Germany (ots/PRNewswire) - - Data From Phase II Studies Investigating BIBW 2992 (Tovok(TM)) and BIBF 1120 (Vargatef(TM)) in NSCLC Patients Presented at 13th World Conference on Lung Cancer (WCLC) INGELHEIM, Germany, August 3 /PRNewswire/ -- Boehringer Ingelheim announced today at the International ...
more
20.07.2009 – 09:06
Boehringer Ingelheim
Head-to-Head Trial Demonstrates Viramune(R)'s Similar Efficacy and Superior Effect on Lipid Profile Compared to atazanavir/ritonavir
Cape Town, South Africa (ots/PRNewswire) - - For Medical Media Outside the US Only Results from the ARTEN* trial presented at the 5th International AIDS Society (IAS) conference in Cape Town, South Africa demonstrated non-inferiority regarding efficacy between Viramune(R) (nevirapine) and ritonavir boosted ...
more
06.07.2009 – 12:10
Boehringer Ingelheim
European Commission Approves Statement on Lipid Improvement for VIRAMUNE(R) Label
Ingelheim, Germany (ots/PRNewswire) - - For Medical Media Outside the US only Boehringer Ingelheim announced today that the European Commission has approved an update of the Summary of Product Characteristics (SmPC) for VIRAMUNE(R) (nevirapine) in the treatment of patients with HIV. The decision followed a positive recommendation by the Committee for Medical Products ...
more
26.06.2009 – 07:49
Boehringer Ingelheim
Boehringer Ingelheim Receives Positive Recommendation From European Scientific Committee for a New Once Daily Mirapexin(R) (Pramipexole) Formulation for the Treatment Of Parkinson's Disease
Ingelheim, Germany (ots/PRNewswire) - - For non-U.S. Healthcare Media Boehringer Ingelheim announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) has issued a positive opinion recommending the approval of a once daily formulation for Mirapexin(R) / ...
more
06.06.2009 – 17:06
Boehringer Ingelheim
New Data From Boehringer Ingelheim's Ongoing Linagliptin Trial Programme Show Promising Safety and Efficacy Results
Ingelheim, Germany (ots/PRNewswire) - - Results From Linagliptin Study in Type 2 Diabetes Patients Who Were Inadequately Controlled on Metformin Therapy Alone, Presented at Major Diabetes Meeting Study results presented for the first time in the scientific sessions of this year's American Diabetes Association Annual ...
more
27.05.2009 – 12:35
Boehringer Ingelheim
Boehringer Ingelheim and the World Stroke Organization Announce Partnership in the World Stroke Academy
Ingelheim, Germany (ots/PRNewswire) - - For Healthcare Media Outside the U.S.A., Canada, and Japan Boehringer Ingelheim announced today that it will become the founding sponsor of the World Stroke Academy, a novel training initiative for stroke professionals being developed by the World Stroke Organization (WSO). ...
more
30.04.2009 – 08:12
Boehringer Ingelheim
Outcome of New Mirapexin(R)/Sifrol(R) (Pramipexole) Study set to Change Treatment of Depressive Symptoms in Parkinson's Disease
Ingelheim, Germany (ots/PRNewswire) - - New Study Shows That Mirapexin(R)/Sifrol(R) (Pramipexole) Relieves Depressive Symptoms of Parkinson's Disease (PD), a Common Non-Motor Symptom Affecting PD Patients' Quality of Life - For Non-US Healthcare Media To view the Multimedia News Release, go to: ...
more
29.04.2009 – 08:06
Boehringer Ingelheim
New Study Results Support Once Daily, Prolonged Release Formulation of Mirapexin(R)/Sifrol(R) (Pramipexole) for the Treatment of Parkinson's Disease
Ingelheim, Germany (ots/PRNewswire) - - Data for the Once Daily Mirapexin(R)/Sifrol(R) (Pramipexole) Formulation Under Development Show Efficacy, Safety and Tolerability Outcomes Comparable to the Current Immediate Release Formulation for the Treatment of Parkinson's Disease For non-US Healthcare Media First data ...
more
28.04.2009 – 08:05
Boehringer Ingelheim
No Increased Risk of Treatment-Induced Augmentation in Restless Legs Syndrome (RLS) Demonstrated in Long-Term Placebo-Controlled Study With Mirapexin(R) / Sifrol(R) (Pramipexole)
Ingelheim, Germany (ots/PRNewswire) - - For Healthcare Media outside the U.S.A. New data presented today at the 61st Annual Meeting of the American Academy of Neurology (AAN), in Seattle, U.S.A. show that augmentation did not significantly differ in RLS patients treated with Mirapexin(R) /Sifrol(R) (pramipexole*) ...
more
20.03.2009 – 00:06
Boehringer Ingelheim
Experts Unite to Create New Online Resource for Restless Legs Syndrome
Ingelheim, Germany (ots/PRNewswire) - - Unique Educational Website 'Under the Covers of Restless Legs Syndrome (RLS)' is Launched on World Sleep Day - For Non-US Healthcare Media The website http://www.rlsunderthecovers.com brings together leading medical experts in the field of Restless Legs Syndrome (RLS) who have undertaken to explain key facts and symptoms of this ...
more
30.01.2009 – 10:03
Boehringer Ingelheim
ECASS 3 Study Receives Recognition From the European Stroke Organisation and The Lancet
Ingelheim, Germany (ots/PRNewswire) - - ESO Recommends Extended Time Window for Actilyse(R) INGELHEIM, Germany, January 30 /PRNewswire/ -- - For Healthcare Media outside the U.S.A., Canada, and Japan Based on key results from the European Cooperative Acute Stroke Study (ECASS 3), the European Stroke Organisation (ESO) now recommends that Actilyse(R) (alteplase) be ...
more
17.11.2008 – 08:06
Boehringer Ingelheim
First Pivotal Trials Begin for Boehringer Ingelheim's Novel Triple Angiokinase Inhibitor Vargatef(TM) (BIBF 1120)
Ingelheim, Germany, November 17 (ots/PRNewswire) - - Progress Continues Across Expanding Oncology Pipeline With Two Compounds now in Phase III Clinical Development and a Potential First-in-Class Polo-Like Kinase 1 Inhibitor Soon to Enter Phase II - For non-US Healthcare Media Boehringer Ingelheim has marked a new ...
more
05.11.2008 – 18:30
Boehringer Ingelheim
Personalising Cancer Care - An Invitation
Ingelheim, Germany, November 5 (ots/PRNewswire) - - For Non-US Healthcare Media Can the quest for personalised medicine in cancer therapy ever be realised? And how far have we come in the journey to personalised cancer care? What lies ahead from a clinical research perspective will be discussed in an international media webcast entitled "Probable or pipedream: could new cancer targets change the outlook for personalised ...
more
31.10.2008 – 14:15
Boehringer Ingelheim
Largest Study of its Kind Reveals Low Sexual Desire is Most Common Female Sexual Problem
Ingelheim, Germany (ots/PRNewswire) - - 1 in 10 Women Experience Distress Associated With the Most Common Form of Female Sexual Dysfunction, yet the Condition Remains Largely Under-Recognised and Under-Diagnosed - For non-US media only Results from the PRESIDE*(1) survey, the largest study assessing the prevalence of female sexual problems, show that low sexual desire ...
more
23.10.2008 – 17:10
Boehringer Ingelheim
Telmisartan (MICARDIS(R)) as Effective as Ramipril But With Better Long-Term Tolerability in High-Risk Cardiovascular Asian Patients
Beijing (ots/PRNewswire) - New results from the landmark ONTARGET(R) Trial show that, in Asian patients at high risk of cardiovascular disease (CVD), telmisartan (MICARDIS(R)) 80mg is as effective as, and significantly better tolerated than, ramipril 10mg in reducing the risk of cardiovascular death, heart attack, ...
more
22.10.2008 – 12:21
Boehringer Ingelheim
Boehringer Ingelheim Broadens Oncology Pipeline With Promising New Data for Potentially First in Class Plk1 Inhibitor
Ingelheim, Germany (ots/PRNewswire) - - BI 6727, a Highly Potent and Selective Plk1 inhibitor, Represents Latest Advance in Company's Plk1 Programme - For non-US Healthcare Media Boehringer Ingelheim's most promising new cell cycle kinase inhibitor and potentially first-in-class compound, BI 6727, has shown ...
more
17.10.2008 – 12:36
Boehringer Ingelheim
From Curiosity to Discovery: Boehringer Ingelheim's Pipeline Update Unveils Novel Investigational Compounds Heralding the Company's Entry Into Type 2 Diabetes
Ingelheim and Biberach, Germany (ots/PRNewswire) - - Boehringer Ingelheim Oncology Pipeline Advances: Two Leading Compounds are Entering Phase III Trials - Boehringer Ingelheim's Investigational Compound in Development for the Treatment of Pre-Menopausal Women Suffering From Hypoactive Sexual Desire Disorder (HSDD) ...
more
25.09.2008 – 09:38
Boehringer Ingelheim
Recent Research Shows Significant Benefits in Acute Ischaemic Stroke With Actilyse(R) Beyond Currently Approved Three Hour Treatment Window
Ingelheim, Germany (ots/PRNewswire) - - For Healthcare Media Outside the U.S.A., Canada, and Japan - Favourable Safety and Efficacy Profile of Actilyse(R) Confirmed by ECASS 3 Study Investigating Treatment in an Extended Time Window up to 4.5 Hours After Symptom Onset First results from ECASS 3 (European Cooperative ...
more
31.08.2008 – 12:35
Boehringer Ingelheim
First Landmark ARB Trial Against Placebo Shows MICARDIS(R) (Telmisartan) Reduces the Risk of Cardiovascular Death, Heart Attack and Stroke in ACE-Intolerant High-Risk Patients(1)
Munich, Germany (ots/PRNewswire) - - TRANSCEND(R), Parallel Trial to ONTARGET(R), Confirms Long-Term Protective Benefits and Excellent Tolerability Profile of Telmisartan 80mg(1) on Top of Current Best Standard of Care MUNICH, Germany, August 31 /PRNewswire/ -- - For non-US Healthcare Media The results of the ...
more

Previous123456789Next